Orexo AB has agreed to advance the successful exploratory feasibility study initiated with Swedish Orphan Biovitrum AB (Sobi) last year, which primarily assessed whether one of its biomolecules could be formulated in the AmorphOX drug delivery platform with retained activity.   The continued collaboration will evaluate if the AmorphOX technology could add unique properties to one of Sobi’s biomolecules.   Orexo has tested enzymes, peptides and proteins in AmorphOX and seen retained act...